[stent thrombosis : A won battle ? (data from the France PCI registry)]

G Rangé1, R Hakim1, C Saint Etienne2

  • 1Hôpitaux de Chartres, Service de Cardiologie, 4 rue Claude Bernard 28630 Le Coudray.

Annales De Cardiologie Et D'Angeiologie
|October 23, 2021
PubMed

Insights

The incidence of stent thrombosis (ST) decreased since 2014 but remains high, with identified risk factors. Despite advancements, ST continues to have a significant impact on patient mortality.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Clinical Research

Background:

  • Stent thrombosis (ST) remains a serious complication following coronary angioplasty.
  • Understanding the incidence, risk factors, and outcomes of ST is crucial for improving patient care.

Purpose of the Study:

  • To assess the 1-year incidence, identify risk factors, and evaluate the prognosis of definite stent thrombosis (ST).
  • To analyze trends in ST rates within a large, multicenter prospective registry in France.

Main Methods:

  • A prospective registry included 35,435 patients undergoing coronary angioplasty with stent implantation from 2014 to 2019.
  • Patients were categorized into ST and control groups to compare outcomes and risk factors.

Main Results:

  • The overall 1-year ST incidence was 0.72%, decreasing in acute coronary syndromes but not chronic ones.
  • Identified risk factors for ST include younger age, diabetes, renal failure, previous angioplasty, LV dysfunction, longer stent length, and lower pre-procedure TIMI flow.
  • 1-year mortality was significantly higher in the ST group (19.14%) compared to the control group (5.82%).

Conclusions:

  • While the incidence of ST has decreased, it has plateaued, indicating a persistent challenge.
  • Risk factors for ST are well-defined, but its high associated mortality necessitates continued efforts in prevention and management.
Abstract

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
56
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
71
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
44
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
68
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
748
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
68